AI generated image of pharmacy shelves. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Biome Australia (ASX:BIO) has revealed it’s achieved record sales revenue for both the half year and full year FY24.

The company posted $13M in sales revenue for full FY24, up +80% vs pcp on an unaudited basis.

Broken down, the company clocked $7M in sales through H2 of FY24; Q4 alone of the financial year saw just short of $4M – up +88% vs pcp.

The full year revenue count exceeds by $500K revised guidance released earlier this year, and, the third consecutive quarter of positive cash flow for the company. It’s also $1.5M higher than guidance released prior to that revision.

Currently, Biome’s number one growth brand is its ‘Activated Probiotics’ line which as closed $12M in revenue through pharmacy sales.

The record half year $7M revenue is the company’s strongest half to date. Quarterly sales revenue through Q4FY24 also reflects a first for the company.

“I am delighted to share Biome’s significant growth in sales revenue for the financial year 2024, up 80% versus the financial year 2023,” Biome Australia founder and MD Blair Vega Norfolk said.

“The $15m run-rate going into FY25 bodes well for another strong year for Biome. I look forward to sharing the detailed analysis of the company’s financial performance and Vision 27 during Q1 FY25.”

Despite the positive news, BIO was down -3.45% to 56cps in late morning trades on Monday.

bio by the numbers
More From The Market Online

Listen: HotCopper Wire Podcast #047 – Maybe just send an email next time, Albo

In this week’s HotCopper Wire episode, Isaac McIntyre and Jonathon Davidson break down (poke holes in) Albo’s national address from 7PM Wednesday, talk
The Market Online Video

Introducing Prairie Lithium: Saskatchewan’s permitted lithium project ready to scale

We've spoken to Prairie Lithium founder Zach Maurer about the explorer's overall mission, right after Macquarie's…
The Market Online Video

US growth, injectable iron pipeline: How AFT Pharma is driving toward $300 million by FY27

AFT Pharmaceuticals (ASX:AFP) is in a red-hot position as we head straight into FY26’s fourth quarter in Australia, and
The Market Online graphic with ASX-branded charts and the text "HotCopper Highlights" centred in white.

HotCopper Highlights, Week 15: Santos, Karoon, Viva all riding the Iran-fuelled Energy rollercoaster

Hello, hello, and welcome to HotCopper Highlights for Week 15, CY26, I’m Isaac McIntyre.